Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.
Blood type
Gemcitabine plus nab-paclitaxel
Interstitial lung disease
Pancreatic cancer
Risk factor
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
30
06
2020
accepted:
29
10
2020
pubmed:
12
11
2020
medline:
24
2
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Drug-induced interstitial lung disease (ILD) is one of the most serious adverse events with a high mortality rate and represents a serious clinical problem. However, gemcitabine plus nab-paclitaxel (GnP)-induced ILD in pancreatic cancer (PC) patients has not been thoroughly investigated. Therefore, we conducted this study to examine the clinical characteristics of GnP-induced ILD and identify risk factors for developing ILD. We retrospectively investigated consecutive patients with PC who received GnP between January 2015 and April 2020. We compared the clinical characteristics and overall survival (OS) according to ILD occurrence and explored risk factors including ABO blood type for developing ILD. Of the 910 patients included in this study, ILD occurred in 20 patients (2.2%). PC patients who developed ILD had a significantly higher frequency of blood type B compared to those without ILD (42% vs. 22%, p ˂ 0.05). Other baseline characteristics including smoking history and current/previous lung disease were not different between the two groups. Median time from initiation of GnP to onset of ILD was 80 days. All patients recovered from ILD and OS was not significantly different according to ILD occurrence. Multivariate analysis revealed that blood type B was an independent risk factor for developing ILD. We demonstrated that GnP-induced ILD occurred in 2.2% of PC patients with no mortality and OS did not differ according to ILD occurrence. Furthermore, we clarified that ABO blood type B was an independent risk factor for developing ILD in PC patients receiving GnP.
Sections du résumé
BACKGROUND
BACKGROUND
Drug-induced interstitial lung disease (ILD) is one of the most serious adverse events with a high mortality rate and represents a serious clinical problem. However, gemcitabine plus nab-paclitaxel (GnP)-induced ILD in pancreatic cancer (PC) patients has not been thoroughly investigated. Therefore, we conducted this study to examine the clinical characteristics of GnP-induced ILD and identify risk factors for developing ILD.
METHODS
METHODS
We retrospectively investigated consecutive patients with PC who received GnP between January 2015 and April 2020. We compared the clinical characteristics and overall survival (OS) according to ILD occurrence and explored risk factors including ABO blood type for developing ILD.
RESULTS
RESULTS
Of the 910 patients included in this study, ILD occurred in 20 patients (2.2%). PC patients who developed ILD had a significantly higher frequency of blood type B compared to those without ILD (42% vs. 22%, p ˂ 0.05). Other baseline characteristics including smoking history and current/previous lung disease were not different between the two groups. Median time from initiation of GnP to onset of ILD was 80 days. All patients recovered from ILD and OS was not significantly different according to ILD occurrence. Multivariate analysis revealed that blood type B was an independent risk factor for developing ILD.
CONCLUSIONS
CONCLUSIONS
We demonstrated that GnP-induced ILD occurred in 2.2% of PC patients with no mortality and OS did not differ according to ILD occurrence. Furthermore, we clarified that ABO blood type B was an independent risk factor for developing ILD in PC patients receiving GnP.
Identifiants
pubmed: 33175298
doi: 10.1007/s10147-020-01827-2
pii: 10.1007/s10147-020-01827-2
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Deoxycytidine
0W860991D6
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-551Références
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30
doi: 10.3322/caac.21590
Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703
doi: 10.1056/NEJMoa1304369
Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825
doi: 10.1056/NEJMoa1011923
Barenboim A, Lahat G, Geva R et al (2018) Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol 44(10):1619–1623
doi: 10.1016/j.ejso.2018.07.057
Hackert T, Sachsenmaier M, Hinz U et al (2016) Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264(3):457–463
doi: 10.1097/SLA.0000000000001850
Ielpo B, Duran H, Diaz E et al (2016) Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol 42(9):1394–1400
doi: 10.1016/j.ejso.2016.01.006
Philip PA, Lacy J, Portales F et al (2020) Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5(3):285–294
doi: 10.1016/S2468-1253(19)30327-9
Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17(6):801–810
doi: 10.1016/S1470-2045(16)00172-8
Hamada T, Yasunaga H, Nakai Y et al (2016) Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. Respirology 21(2):338–343
doi: 10.1111/resp.12665
Furuse J, Gemma A, Ichikawa W et al (2017) Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 47(9):832–839
doi: 10.1093/jjco/hyx075
Gemma A, Kudoh S, Ando M et al (2014) Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105(12):1584–1590
doi: 10.1111/cas.12550
Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966
doi: 10.1200/JCO.2006.07.9525
Okusaka T, Furuse J, Funakoshi A et al (2011) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102(2):425–431
doi: 10.1111/j.1349-7006.2010.01810.x
Nishimura M, Toyoda M, Takenaka K et al (2016) The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 77(6):1165–1170
doi: 10.1007/s00280-016-3026-6
Udagawa C, Horinouchi H, Shiraishi K et al (2019) Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PLoS ONE 14(10):e0223371
doi: 10.1371/journal.pone.0223371
Li Y, Liu L, Huang Y et al (2020) Association of ABO polymorphisms and pancreatic cancer/cardiocerebrovascular disease: a meta-analysis. BMC Med Genet 21(1):41
doi: 10.1186/s12881-020-0975-8
Xu HL, Cheng JR, Zhang W et al (2014) Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population. Chin J Cancer 33(2):68–73
doi: 10.5732/cjc.013.10060
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458
doi: 10.1038/bmt.2012.244
Ioka T, Katayama K, Tanaka S et al (2013) Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan. Jpn J Clin Oncol 43(2):139–145
doi: 10.1093/jjco/hys211
Ogawa Y, Suzuki E, Mikata R et al (2018) Five cases of interstitial pneumonitis due to gemcitabine and nab-paclitaxel combination treatment in pancreatic cancer patients. Pancreas 47(7):e42–e43
doi: 10.1097/MPA.0000000000001088
Irie H, Suzuki R, Takagi T et al (2020) Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis. Cancer Chemother Pharmacol 85(3):517–523
doi: 10.1007/s00280-019-03983-3
Kashiwada T, Saito Y, Terasaki Y et al (2019) Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. Jpn J Clin Oncol 49(2):165–173
doi: 10.1093/jjco/hyy180
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41(9):986–990
doi: 10.1038/ng.429
Li SS, Zhou CY, Liao R et al (2020) ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Medicine (Baltimore) 99(14):e19413
doi: 10.1097/MD.0000000000019413
Zhang BL, He N, Huang YB et al (2014) ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 15(11):4643–4650
doi: 10.7314/APJCP.2014.15.11.4643
Duan YF, Zhu F, Li XD et al (2015) Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis. Tumour Biol 36(7):5081–5087
doi: 10.1007/s13277-015-3159-y
Melzer D, Perry JR, Hernandez D et al (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 4(5):e1000072
doi: 10.1371/journal.pgen.1000072
Paré G, Chasman DI, Kellogg M et al (2008) Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 4(7):e1000118
doi: 10.1371/journal.pgen.1000118
Barbalic M, Dupuis J, Dehghan A et al (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19(9):1863–1872
doi: 10.1093/hmg/ddq061
Qi L, Cornelis MC, Kraft P et al (2010) Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 19(9):1856–1862
doi: 10.1093/hmg/ddq057